Top Broker Regulation Stories
GLP-1 drugs are fueling a new wave of health care M&A
By Kristen SmithbergDemand for obesity and metabolic therapies is accelerating deal activity as pharma companies shift from blockbuster drugs to platform control.
Brokers, human resources manager and other benefits professionals were thrust into the regulatory environment with the passage of the Affordable Care Act in 2010. As health care reform continues to evolve in a post-ACA world, we provide updates on the legislative front, and analysis and advice regarding the current regulatory environment, along with insights into what's next.
Demand for obesity and metabolic therapies is accelerating deal activity as pharma companies shift from blockbuster drugs to platform control.